Publication Date
1-1-2023
Journal
Frontiers in Immunology
DOI
10.3389/fimmu.2023.1167965
PMID
37781368
PMCID
PMC10538569
PubMedCentral® Posted Date
9-14-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, HIV-1, CD4-Positive T-Lymphocytes, HIV Infections, HIV Antibodies, Cell Line, HIV Seropositivity, Single-Chain Antibodies, HIV, CD4 + T cells, dendritic cells, neutralization, single chain variable fragments, glycosyl phosphatidylinositol, immunotherapy
Abstract
HIV-1 infection of target cells can occur through either cell-free virions or cell-cell transmission in a virological synapse, with the latter mechanism of infection reported to be 100- to 1,000-fold more efficient. Neutralizing antibodies and entry inhibitors effectively block cell-free HIV-1, but with few exceptions, they display much less inhibitory activity against cell-mediated HIV-1 transmission. Previously, we showed that engineering HIV-1 target cells by genetically linking single-chain variable fragments (scFvs) of antibodies to glycosyl phosphatidylinositol (GPI) potently blocks infection by cell-free virions and cell-mediated infection by immature dendritic cell (iDC)-captured HIV-1. Expression of scFvs on CD4
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Biology Commons, Genetic Phenomena Commons, Immunotherapy Commons, Medical Genetics Commons, Medical Specialties Commons